Pixelgen Raises $15.5M for Cell Architecture Mapping

Pixelgen Technologies, a Stockholm-based innovator in cellular analysis, has successfully closed a €13.26 million (approximately $15.5 million) Series B funding round. This significant capital infusion is earmarked to propel the company's global expansion and further refine its groundbreaking spatial mapping technology for cell-surface proteins. The oversubscribed round saw participation from both new and existing backers, underscoring strong market confidence in Pixelgen's disruptive approach to understanding cellular architecture.

Leading the investment was Flat Capital, with significant contributions also coming from returning investors Industrifonden and Navigare Ventures. The influx of capital will empower Pixelgen to scale its commercial operations, enhance its product portfolio, and broaden its team. In conjunction with the financing, Rickard El Tarzi, CEO of Flat Capital, and life sciences expert Ramon Felciano, Ph.D., have joined Pixelgen's board of directors, bringing valuable strategic guidance and industry experience.

Pixelgen's core innovation lies in its Proxiome Kit, a high-throughput platform designed to map the molecular organization of cell surfaces at nanoscale resolution. Unlike traditional proteomic methods that primarily focus on protein quantity, Pixelgen's technology reveals the spatial relationships and clustering of proteins. This detailed architectural view offers researchers unprecedented insights into cell states, disease progression, and responses to therapeutic interventions, particularly within fields like immunology, hematology, and oncology. The company's proprietary Proximity Network Assay underpins this capability, enabling high-dimensional analysis of single-cell surface architecture.

The demand for such advanced cellular insights is growing rapidly within the life sciences sector. As researchers delve deeper into complex biological systems, understanding the spatial arrangement of molecules on cell surfaces is becoming critical for identifying novel drug targets and developing more effective treatments. The global market for life science tools and services is projected to continue its upward trajectory, driven by advancements in genomics, proteomics, and single-cell analysis. Pixelgen's technology is well-positioned to capture a significant share of this expanding market.

Simon Fredriksson, Ph.D., CEO and co-founder of Pixelgen, expressed enthusiasm for the funding, stating, "This financing provides us with the necessary resources to expand globally as demand for our Proxiome Kit and our data analysis and visualization software grows. We are thrilled to welcome Flat Capital and appreciate the continued confidence from Navigare and Industrifonden. Their support will accelerate our commercial reach, team growth, and product development, bringing molecular cell architecture to a wider research community and new applications."

This Series B follows a series of strategic funding milestones for Pixelgen. The company previously secured approximately €6.24 million ($7.3 million) in a Series A round in October 2023, also involving Industrifonden and Navigare Ventures. Furthermore, in June 2025, Pixelgen was awarded a substantial grant and equity financing of €12.5 million ($14.7 million) from the European Innovation Council (EIC) Accelerator. These previous successes highlight the company's consistent progress and the increasing investor appetite for its innovative solutions.